UNITED NEWS INTERNATIONAL (UNI) — A medicine made from marijuana is well on its way to becoming the first cannabis-derived prescription drug on the U.S. market.

An advisory committee to the U.S. Food and Drug Administration recommended the medicine for federal approval April 19.

The drug is called Epidiolex. It’s made by U.K.-based company GW Pharmaceuticals and is designed to treat seizures in children with severe forms of epilepsy.

It’s made from an ingredient in cannabis called cannabidiol, or CBD. Unlike the psychoactive component in marijuana known as THC, CBD does not produce a high.

A 13-member group of FDA advisors voted unanimously in favor of supporting the drug based on the success of clinical trials.

While the approval of an advisory committee doesn’t guarantee the FDA will follow suit, The Washington Post reports the administration usually does.

The FDA is expected to announce its decision on Epidiolex June 27.